The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Outcomes & predictors of survival in patients with R/R DLBCL: a population-based analysis
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, discusses the challenges of understanding the patient population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting findings from a population-based analysis that evaluated patients with R/R DLBCL in Canada. Dr Kuruvilla notes that older patients tend to have poorer outcomes, with time to progression remaining a key factor in predicting overall survival. The study also suggests that CAR T-cell therapy may offer benefits, even from a population-level perspective, paving the way for further research on the impact of these novel therapies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
